User contributions for MKraft

12:0812:08, 29 July 2024 diff hist −1 Fallon et al. (2017) II: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies No edit summary
12:0212:02, 29 July 2024 diff hist +1,073 Fallon et al. (2017) I: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies No edit summary
11:4211:42, 29 July 2024 diff hist +642 Jatoi et al. (2002): Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study No edit summary
11:3411:34, 29 July 2024 diff hist +6 Grimison et al. (2020): Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial No edit summary
11:1611:16, 29 July 2024 diff hist −4 Côté et al. (2016): Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled Trial No edit summary
11:1011:10, 29 July 2024 diff hist +953 Lichtmann et al. (2018): Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain No edit summary
11:0111:01, 29 July 2024 diff hist +770 Lichtmann et al. (2018): Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain No edit summary
10:5110:51, 29 July 2024 diff hist +19 Portenoy et al. (2012): Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial No edit summary
10:4610:46, 29 July 2024 diff hist +1,543 Portenoy et al. (2012): Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial No edit summary

09:4709:47, 16 July 2024 diff hist +13 Khodabakhshi et al. (2019): Feasibility, Safety, and Beneficial Effects of MCT-Based Ketogenic Diet for Breast Cancer Treatment: A Randomized Controlled Trial Study No edit summary
09:4509:45, 16 July 2024 diff hist −14 Freedland et al. (2020): A Randomized Controlled Trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer: Carbohydrate and Prostate Study 2 (CAPS2) No edit summary
09:4309:43, 16 July 2024 diff hist +16 Cohen et al. (2018): Favorable Effects of a Ketogenic Diet on Physical Function, Perceived Energy, and Food Cravings in Women with Ovarian or Endometrial Cancer: A Randomized, Controlled Trial No edit summary
09:3609:36, 16 July 2024 diff hist +26 Puri et al. (2010): Lycopene in treatment of high-grade gliomas: A pilot study No edit summary
09:3509:35, 16 July 2024 diff hist +4 Paur et al. (2017): Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA No edit summary
09:3209:32, 16 July 2024 diff hist +8 Mahmoodnia et al. (2017): Ameliorative effect of lycopene effect on cisplatin-induced nephropathy in patients No edit summary
09:2909:29, 16 July 2024 diff hist +36 Chan et al. (2011): Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer No edit summary

08:2408:24, 15 July 2024 diff hist +20 Yap et al. (2017): Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial No edit summary

10:1110:11, 11 July 2024 diff hist +2,031 Fallon et al. (2017) I: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies No edit summary
10:0810:08, 11 July 2024 diff hist +1,549 Fallon et al. (2017) I: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies No edit summary
10:0410:04, 11 July 2024 diff hist +162 Fallon et al. (2017) I: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies No edit summary
10:0210:02, 11 July 2024 diff hist +1,785 Fallon et al. (2017) I: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies No edit summary
09:3309:33, 11 July 2024 diff hist −6 Fallon et al. (2017) I: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies No edit summary
09:2909:29, 11 July 2024 diff hist +2,192 Fallon et al. (2017) I: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies No edit summary
09:0509:05, 11 July 2024 diff hist −1 Fallon et al. (2017) I: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies No edit summary
09:0409:04, 11 July 2024 diff hist 0 Fallon et al. (2017) II: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies No edit summary
09:0309:03, 11 July 2024 diff hist +3,650 Fallon et al. (2017) II: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies No edit summary
09:0209:02, 11 July 2024 diff hist +3,651 Fallon et al. (2017) I: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies No edit summary
08:5908:59, 11 July 2024 diff hist +16 Fallon et al. (2017) I: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies No edit summary
08:5908:59, 11 July 2024 diff hist +1 Fallon et al. (2017) II: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies No edit summary
08:5808:58, 11 July 2024 diff hist +14 Fallon et al. (2017) II: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies No edit summary
08:5708:57, 11 July 2024 diff hist +2,556 N Fallon et al. (2017) II: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies Created page with "{{Reference |Reference=Publication: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies }} {{Study Note |Study Note=This is the second study of Fallon et al. (2017): Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, rando..."
08:5408:54, 11 July 2024 diff hist +2,562 N Fallon et al. (2017) I: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies Created page with "{{Reference |Reference=Publication: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies }} {{Study Note |Study Note=This study is the first study of Fallon et al. (2017): Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind,..."
08:4908:49, 11 July 2024 diff hist −1 Publication: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies No edit summary
08:4808:48, 11 July 2024 diff hist −3 Publication: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies No edit summary
08:4808:48, 11 July 2024 diff hist +2,626 N Publication: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies Created page with "{{Publication |Title=Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies |Topic=Cannabinoids |Author=Fallon, M T; Lux, E A; McQuade, R; Rossetti, S; Sanchez, R; Sun, W; Wright, S; Lichtman, A H; Kornyeyeva, E |Year=2017 |Journal=British Journal of Pain |DOI=https://doi.org/10.1177/2049463717710042 |Authors Abstract=Backgrou..."

11:4511:45, 10 July 2024 diff hist +18 Jatoi et al. (2002): Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study No edit summary
11:0111:01, 10 July 2024 diff hist +10,926 Jatoi et al. (2002): Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study No edit summary
09:5109:51, 10 July 2024 diff hist +2,269 Publication: Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study No edit summary

05:0005:00, 8 July 2024 diff hist +2,843 Publication: Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial No edit summary

12:1312:13, 1 July 2024 diff hist +12,364 Côté et al. (2016): Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled Trial No edit summary
11:0311:03, 1 July 2024 diff hist +1,704 N Publication: Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled Trial Created page with "{{Publication |Title=Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled Trial |Topic=Cannabinoids |Author=Côté, M; Trudel, M; Wang, C; Fortin, A |Year=2016 |Journal=Annals of Otology, Rhinology & Laryngology |DOI=https://doi.org/10.1177/0003489415612801 |Authors Abstract=Objectives: Patients treated for head and neck carcinomas experience a significant deterioration of their qua..." current

06:5306:53, 28 June 2024 diff hist +8,633 Newling et al. (1995): Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group No edit summary
05:4405:44, 28 June 2024 diff hist +9,329 Mahmoodnia et al. (2017): Ameliorative effect of lycopene effect on cisplatin-induced nephropathy in patients No edit summary

29 July 2024

16 July 2024

15 July 2024

12 July 2024

11 July 2024

10 July 2024

8 July 2024

1 July 2024

28 June 2024